H.C. Wainwright raised the firm’s price target on Ocular Therapeutix (OCUL) to $15 from $14 and keeps a Buy rating on the shares following the Q3 report. The firm says SOL-1 is slated to complete enrollment by the end of 2024 with topline data expected in Q4 of 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score a data driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL: